Cetuximab as Induction Treatment in Head and Neck Squamous Cell Carcinoma (HNSCC)

PHASE2CompletedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

November 30, 2012

Study Completion Date

August 31, 2013

Conditions
Head and Neck Neoplasm
Interventions
DRUG

Cetuximab

400 mg/m2 first dose, then 250 mg/m2 weekly for 9 weeks

DRUG

Docetaxel

75 mg/m2, day 1 of every 3 weeks for 9 weeks (3 cycles)

DRUG

Cisplatin

75 mg/m2, day 1 of every 3 weeks for 9 weeks (3 cycles)

Trial Locations (1)

110-744

Seoul National University Hospital, Seoul

All Listed Sponsors
collaborator

Clinical Research Center for Solid Tumor, Korea

OTHER

lead

Seoul National University Hospital

OTHER